© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Maytansine, a potent cytotoxic agent, sprang into the world’s attention during the 1970s. Originally found in the bark of the Ethiopian shrub Maytenus ovatus, this substance made waves due to its microtubule-inhibiting properties. Pure maytansine showed promise against cancer cells in a petri dish, but human trials revealed toxicities at even low dosages. The raw power of maytansine came with a heavy burden of side effects, and progress stalled for decades. Eventually, researchers shifted to synthetic derivatives, with DM4 emerging as a key player. Scientists explored antibody-drug conjugates (ADCs) to deliver DM4 more selectively, avoiding the scattershot toxicity of free maytansine. DM4 has now carved a place as a reliable payload in targeted cancer therapies, a development that reshaped thinking around how potent drugs can reach their mark without laying waste to healthy cells.
Dm4, known formally as N2’-deacetyl-N2’-(4-mercapto-1-methylbutyl)-maytansine, serves as a modified version of maytansine designed to connect safely to monoclonal antibodies. The idea centers on creating a bridge from a proven, deadly toxin to the precision-guided missile of modern immunotherapy—the monoclonal antibody. Commercially, DM4 surfaces in clinical and research settings as a pale, off-white powder, often shipped with desiccants and stored at sub-zero temperatures to maintain stability. Its molecular formula, C41H66ClN3O10S, hints at complexity, and at a molecular weight just north of 800 Daltons, this molecule is heavy for a cytotoxin. Its value stems from the ability to nestle inside an antibody–drug conjugate, where it slides silently into tumors, delivered like a Trojan horse.
Anyone who has worked with DM4 can testify to its finicky nature. Sparingly soluble in aqueous solutions, DM4 tends to mix better with organic solvents like DMSO or ethanol. Its crystalline nature aids in handling but presents challenges during formulation. The compound holds a melting point in the range of 120-123°C, reflecting its structurally dense backbone. Chemically, the sulfhydryl group sits at the heart of its reactivity, ready to create stable thioether bonds with linker technologies. Researchers quickly learn to limit DM4's exposure to light and moisture, as hydrolysis and degradation compromise potency. Storage calls for vigilance—ultra-low freezers and amber vials help retain its punch.
DM4’s technical specs matter most in a pharmaceutical setting, where purity, identity, and substance characterization move off the label and into compliance protocols. Most suppliers document purity above 98% by HPLC analysis, and batch certificates track everything from water content to residual solvents. Labels spell out safety, batch, storage, and reconstitution data, usually supported by QR codes or barcodes for traceability. Serialization helps in regulatory audits, especially as DM4 moves through clinical supply chains. GMP compliance sets the baseline, but companies working in ADC development hold materials to even tighter specs due to the high clinical stakes.
Manufacturers synthesize DM4 by semi-synthetic modification of natural maytansine or fully synthetic approaches. The most common route hinges on introducing a 4-mercapto-1-methylbutyl group at the C19 position of maytansinol, achieved through a series of precise chemical reactions—most notably acylation and selective thiolation steps. Skilled organic chemists rely on high-vacuum filtration and chromatography to coax and capture high purity fractions. Every incremental adjustment in pH, temperature, and solvent mixture can make or break the outcome. To produce scalable amounts, process engineers join the fray, balancing cost and safety through controlled batch operations and diligent waste handling.
In the lab, DM4’s reactivity revolves around its free sulfhydryl group. The –SH group allows for the robust attachment of DM4 to antibody linkers, forming non-reducible thioether bonds, usually via maleimide or similar linker technologies. This specific site-directed conjugation allows researchers to tweak drug-antibody ratios—critical for tuning efficacy and minimizing off-target effects. Chemists sometimes modify the linker region to release DM4 only upon exposure to the tumor cell’s unique enzymes, adding another layer of selectivity. Some approaches use hydrazone or peptide linkers that respond to lysosomal conditions. In terms of further chemical tweaks, teams have explored disulfide bridges to enable cleavable configurations, aiming to optimize release kinetics inside cancer cells.
Over its history, DM4 has earned a handful of monikers, with names like mertansine or N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine surfacing in academic literature. Sometimes it appears under proprietary labels as “Emtansine DM4,” especially in company-developed ADC products. You may also see it referenced by trade names or abbreviations in clinical trial registries, such as SAR3419 or in combinations like SAR650984-DM4. These aliases can create confusion in supply chains and search engines, making CAS registry numbers a vital checkpoint for purchasing.
As a cytotoxic compound, DM4 presents real hazards to both lab personnel and environment. Direct exposure can lead to acute toxicity; accidental skin contact or inhalation spells trouble due to its potency. Operating procedures demand closed systems, biological safety cabinets, and double-gloving for all handlers. Labs post prominent hazard warnings, and training in cytotoxin handling counts as non-negotiable. Medical monitoring targets those with routine DM4 exposure, looking for early signs of blood or liver toxicity. Environmental standards require chemical waste segregation and on-site destruction, with solvent containment and record-keeping for regulatory compliance. Anyone transporting DM4, even within the same facility, must log movement and use triple packaging at minimum.
Dm4 finds its voice in targeted cancer therapy, mated to monoclonal antibodies against Her2 or CD33, among others. These ADCs sail through clinical trials and in some cases reach patients with advanced, otherwise untreatable tumors. Trastuzumab emtansine (T-DM1) marked the point where DM4 broke out as a household—if specialist—name, redefining chemotherapy for HER2-positive breast cancer. ADC technology’s logic is simple: transport lethal drugs directly into the tumor, limit systemic damage. Research centers and pharmaceutical giants continue to push for broader indications, including hematological malignancies and solid tumors with new surface markers. Preclinical studies occasionally dip DM4 into other therapeutic spaces, but cancer remains the mainstay.
Research into Dm4 isn’t slowing down. The main challenge revolves around improving how efficiently the drug is delivered and released inside cancer cells. Scientists build new linkers, study multidrug resistance, and push the boundaries of what ADCs can do. Tumor heterogeneity, antigen escape, and off-target toxicity still pose problems, so biologists and chemists experiment with bispecific antibodies, engineered Fc domains, and even dual-payload ADCs. Every paper published adds a brick to our understanding, sparking hope for more personalized cancer treatment.
Studying DM4’s toxicity forced the community to rethink safety nets. Early work flagged neurotoxicity and hepatotoxicity as stubborn adversaries with naked DM4 or maytansine use. Modern ADCs dial down some risks, but payload escape and linker instability remind us there’s no free lunch. Teams run animal models exploring dose-limiting toxicities in organ systems, and pharma companies push advanced analytics to pick up even mild adverse effects in early trials. Real-world data accumulates as patients go through treatment, feeding directly into updated dosing guidelines and risk assessments.
The horizon for DM4 stays bright, fueled by new targets, smarter conjugation chemistry, and digital-tailored patient selection. AI-driven analytics sift through genetic data to pinpoint who might gain the most from DM4-based ADCs. As drug delivery systems become more refined, there’s growing push for combo therapies—pairing DM4 with immune checkpoint inhibitors or novel bispecifics. Manufacturing innovations, like continuous flow chemistry or green solvent systems, promise to cut waste and bring down costs. On the regulatory side, tightening standards challenge companies to produce ever more robust safety data, but the field bends toward higher-impact therapies meeting real clinical need.
Maytansine DM4 stands out among the newer cancer drugs, not for its origins in a high-tech lab, but because it begins as a natural toxin. Years ago, researchers started looking at Maytansine after spotting how it poisons cells by throwing their insides into chaos. Its job: stop cancer cells from dividing and multiplying. Lab studies showed the compound does this by mucking up microtubules, the tiny tubes that act like highways for cell division. But using it alone proved too rough on healthy cells—imagine trying to clear weeds by setting fire to a whole field.
A clever workaround: link DM4, a derivative of the original Maytansine, to an antibody. These antibodies are trained to look for targets that show up on cancer cells and mostly leave healthy ones alone. The resulting medication, often called an antibody-drug conjugate, brings DM4 right to the enemy, like a guided missile, and delivers the punch exactly where it’s needed. Tissues without those targets aren’t hit nearly as hard, so patients see fewer side effects compared to traditional chemo.
Patients who walk into cancer clinics these days have often already heard the phrase “targeted therapy.” The hope is always for something with more kick against tumors and less collateral damage to good cells. DM4-based drugs, including those built from Maytansine derivatives, support this approach. In real-life practice, oncologists often use DM4 conjugates to treat women with certain types of breast cancer. Kadcyla, known generically as ado-trastuzumab emtansine, links DM1 (a relative of DM4) to an antibody that searches out HER2 proteins found in abundance on some breast cancers. Early versions of these drugs help patients who’ve seen too many treatments fail. For many, it’s a lifeline when traditional therapies no longer work.
The promise goes beyond breast cancer. DM4-linked drugs are now entering trials for lung cancer, ovarian cancer, and others. Some newer versions take aim at markers popping up on solid tumors that once shrugged off older treatments. That means even people with rare or tricky cancers might benefit down the road.
It’s important not to gloss over the complications that come with drugs built on DM4. Keeping healthy cells safe depends almost entirely on that antibody hitting only the right targets. Some side effects—low blood counts, liver irritation, nerve pain—do show up, especially if the target is found in a few healthy tissues, or if there’s “off-loading” of DM4 before it gets to cancer. Drug resistance can build up, a problem seen in many targeted meds. Cancer cells find sneaky ways to lose the surface proteins that the antibody looks for, slip out DM4, or patch up the damage internally.
Researchers now run trials looking to pair these drugs with immunotherapy or combine them with other antibody therapies. There’s a need for better screening to check which patients have the right targets. Diagnostic tools like immunohistochemistry and emerging blood tests play a big role in figuring out who’s most likely to benefit. As we learn more, the hope is to keep pushing antibody-drug conjugates like DM4 toward earlier stages in treatment, or even finding new combinations that keep drug resistance at bay.
What started as a poison from a plant has grown into precision medicine for cancer care. This shift tells us a lot about the way forward: building smart therapies with roots in nature, guided by the best that science and experience together can provide.
Cancer pulls no punches, and every year people face tough battles against aggressive types of tumors. Traditional chemotherapy tries to wipe out cancer cells, but side effects hit hard because these drugs do not choose between healthy and sick cells. The idea behind DM4, a synthetic version of maytansine, moves in a different direction than the old, scattershot approach.
DM4 attaches to special antibodies, forming what people in medicine call an “antibody-drug conjugate." These antibodies have a nose for targets that stick out on cancer cells, almost like how a bloodhound picks up one person’s scent over a crowd. By locking onto proteins only cancers display, the antibody drags DM4 straight to the tumor. The rest of the body gets spared most collateral damage.
For someone who has watched friends lose their appetite, strength, or hope during chemotherapy, the value of a targeted approach like DM4 stands out. Infusions that single out cancer almost feel like a sniper’s bullet compared to a blanket bombing raid. Less healthy tissue damaged means people feel stronger, bounce back faster, and, sometimes, fight off cancer longer.
DM4 makes its presence known only after it sneaks into a cancer cell. Once the antibody guides it in, the cell breaks down the antibody-drug link, freeing DM4. The drug then messes up the internal skeleton that all cells use to divide and survive. Without a working skeleton, cancer cells can’t create new copies of themselves. Eventually, most die off.
Doctors and researchers noticed early success, especially in breast cancers with the HER2 protein flagged by the right antibody. Drugs like trastuzumab emtansine (T-DM1) have already reached clinics and brought new hope to patients who had run out of other options. Life can stretch longer thanks to DM4’s action, and people sometimes stay off harsher treatments.
Clinical studies speak clearly. Women in trials with advanced HER2-positive breast cancer saw longer times before tumors grew when treated with T-DM1 compared to regular chemo. Fewer harsh reactions showed up too. Confusion or hair loss, expected with standard drugs, happened less often. Instead, some patients mainly faced symptoms like low platelets, which doctors know how to watch and treat.
Researchers keep looking for more targets, hoping to pair DM4 with new antibodies to treat lung, ovarian, and stomach cancers. Several cancer centers are now enrolling patients in studies using different forms of the DM4 “payload,” trying to answer how far this tool can go.
No one solution fits every person or every type of cancer, but DM4 signals a shift toward smarter, safer medicines. Doctors and scientists have started to believe deeply in this targeted warfare. More research dollars keep flowing as companies race to invent new antibody combos that bring DM4 to different tumors. Patients and families tired of scorched-earth approaches watch closely.
Countless tough fights still lie ahead for people with cancer. Targeted drugs like DM4 give fresh choices, less fear of the cure, and a much-needed boost in day-to-day hope for millions around the world.
DM4, also called Maytansine DM4, isn’t a medicine many folks outside of specialized clinics hear about often, but it’s making its way into new cancer treatments all the time. The main idea comes down to attaching a very strong cell-killing agent (DM4) to helpful antibodies. This combo-solution gets cancer drugs right where they’re needed. That approach, while targeted, doesn’t mean side effects stop being a concern.
People taking drugs containing this compound, like some antibody-drug conjugates used in breast cancer, often run into some predictable issues. Tiredness, nausea, and low blood counts are high on the list. I’ve spoken with people in treatment who say this tiredness isn’t the usual “I stayed up too late”—it’s the sort of fatigue that makes getting out of bed feel like a battle. Doctors will warn about fevers, bruising, and even mouth sores because these are signs the medicine has hit bone marrow and fast-dividing cells, not just tumor tissue.
There’s a unique kind of nerve pain, too. Hands might tingle, feet might go numb. Laundry, typing, or holding a spoon becomes frustrating. Research published in journals like the Journal of Clinical Oncology confirm nearly half of people in major trials run into these nerve symptoms. Over time, those side effects, if not reported quickly, stick around longer than most people realize.
One side effect that worries cancer doctors, and the folks living with cancer, is low platelet counts. With low platelets, even a small cut can turn serious. Blood transfusions might become necessary, and regular blood tests become a fact of life. Another risk to keep an eye on: Liver irritation. Some patients’ numbers drift up slowly, but sometimes, the liver gets inflamed fast. Abdominal pain, yellowing eyes, and dark urine call for phone calls, not waiting for the next appointment.
The eyes tend to suffer, too. Dryness, blurry vision, and stinging pop up more often than most expect. It’s common enough that clinics often keep artificial tears on hand, and nurses check vision changes every visit. Headaches come and go, but trouble concentrating—what some call “chemo brain”—makes bills and emails a hurdle.
Side effects rarely stop with the body. They reach into jobs, relationships, even daily mood. Many find work gets interrupted by medical appointments or sick days. Eating becomes harder when mouth sores and nausea combine. Family caregivers feel burned out, especially if their loved one needs help with walking or dealing with infections. Kids and spouses see these changes up close, and it’s impossible to shield them from all the stress.
Having honest conversations with a cancer care team matters most. Reporting numb fingers early could spare nerves from permanent damage. Doctors now adjust doses based on early reports of side effects, and there’s good evidence that catching problems early prevents longer delays or hospital stays later. Support groups and social workers have stepped up to help, and treatments for nausea, fatigue, or pain have improved. Patients swapping notes in waiting rooms have always taught me there’s no “one size fits all”—but talking openly about the tough parts helps everyone push forward.
Advances in medicine keep pushing for targeted drugs that attack cancer cells but leave everything else alone. But right now, drugs like DM4 come with some trade-offs. Knowing what to expect lets people prepare. The more honest the conversation about side effects, the more likely everyone can face these challenges together—and find ways to carry on with daily life as best as possible.
A lot of people reading about breakthrough cancer treatments come across the word “DM4” or “Maytansine DM4” and wonder if this active ingredient itself holds an FDA approval. Digging into this issue, it becomes obvious that understanding how drug approvals work helps patients, physicians, and investors make smart decisions. Personally, I’ve followed news of cancer treatments closely for years, and confusion around antibody-drug conjugates, and their individual components, always seems to trip people up.
DM4 isn’t a “drug” you receive on its own at the clinic. DM4 is a cytotoxic agent, a chemical bullet attached to certain cancer drugs — known as antibody-drug conjugates (ADCs). Companies design ADCs to deliver powerful toxic agents, like DM4, right to tumors, sparing more of the healthy tissue around them. In simple terms: DM4 is the toxin, the antibody is the targeting agent. The company ImmunoGen developed DM4 specifically for use in these conjugates.
The real question everyone asks: Has the FDA given the stamp of approval to DM4 itself? To set things straight, DM4 by itself does not carry FDA approval. The agency doesn’t approve the component; it approves the whole ADC. What you see on a pharmacy shelf, or in a hospital infusion room, is the complete product—not raw DM4.
The U.S. Food and Drug Administration points its regulatory power at finished drugs. Individual parts—like DM4—pass through safety studies, but they never become approved “standalone” agents. DM4 gets evaluated as part of each whole combination. Mylotarg, Kadcyla, and similar drugs don’t rely on DM4; they’re built on other toxins. The notable DM4-based drug, Elahere (mirvetuximab soravtansine-gynx), won FDA approval in late 2022 for certain ovarian cancers. Importantly, it’s the whole product that’s approved, not DM4 on its own.
Misunderstanding about what’s FDA approved can lead to disappointment for patients searching for hope, or confusion for people following clinical trials news. Personally, I’ve seen patients rush to ask for “the new DM4 approval” after hearing about a positive trial — only to find out their doctor can’t order DM4, but only a specific ADC that uses it. If pharma companies and the media explained clearly, families and patients would save energy and stress searching for treatments unavailable or still unproven.
Following the facts keeps choices grounded. The FDA’s Drugs@FDA database or respected cancer centers like Memorial Sloan Kettering or Dana-Farber Cancer Institute are good places to verify whether a therapy is truly approved—and for what conditions. News releases can sometimes hype results, but without FDA clearance, components like DM4 stay out of reach. This system works to protect safety, not to slow down new cures.
Doctors and care teams carry the weight of translating these technical details to patients without the jargon. I remember seeing a friend’s confusion lift after one empathetic nurse took time to explain the difference between a compound winning media coverage and an actual treatment being available. Responsibility falls on everyone—companies, regulators, and clinicians—to support honest conversations about what’s real today and what remains in the pipeline.
Cancer puts patients and families on new ground, and treatment options change often. DM4, a derivative of maytansine, plays a role in targeted cancer therapies. This compound doesn't show up as a pill you buy at the local pharmacy. It works as a chemotherapy agent but travels into the body differently.
DM4 arrives not by itself, but as a payload attached to an antibody. Scientists figured out that many tumors display special markers on their surfaces. Researchers developed antibodies designed to stick to those markers. By linking DM4 to these antibodies, doctors deliver the drug right to cancer cells, mostly avoiding healthy ones. This combination forms what's called an antibody-drug conjugate, or ADC.
Most DM4-based ADCs, like trastuzumab emtansine (T-DM1), come as intravenous (IV) infusions. Nurses mix the medicine with a fluid, then set up an IV line. It usually takes nearly thirty minutes to ninety minutes for each dose. The specific action plan depends on the treatment being used and the patient’s health. One round might mean a single infusion every three weeks, although some regimens bring patients back sooner.
Using an IV leaves patients in a clinical setting during treatment. Some folks describe the hospital experience as draining, but others find peace in knowing skilled people stand nearby. While antibody targeting spares many healthy cells, DM4 still packs a punch. Side effects show up, with fatigue, low blood counts, and nausea ranking among the most common. Some people lose platelets. Other patients develop liver issues. Doctors monitor lab work at every visit, dialing in doses as needed and pausing if things look rough. The balance between aggression against cancer and attention to patient safety demands experience and careful study.
A strong relationship with the oncology team matters a lot. My neighbor, who finished several rounds of an ADC containing DM4, liked to joke that the nurses knew his veins better than he did. He valued their patience and skill. Consistent support helps most people stick with the schedule, especially when the routine grows tiring. Consistent hydration, adjusting daily plans, and talking about symptoms lead to better outcomes. Patients who bring up lingering nausea or headaches right away often avoid bigger problems down the line.
Innovation doesn't rest. Clinical teams campaign for more convenient ways to deliver promising drugs like DM4. Some researchers explore other delivery routes, aiming for shorter clinic times or at-home care possibilities. Real progress relies on honest reporting from patients and ongoing science. As things stand, IV infusion remains the method for DM4-based ADCs. For people facing cancer, maintaining a human touch in clinical settings makes a notable difference.
| Names | |
| Preferred IUPAC name | N-[(3R,4S,5S,6E,8R,9S,10Z,12S,13S,14S,16R)-13-acetoxy-4,9,14-trimethoxy-3,12-dimethyl-5,11-dioxo-8,16-bis(2-methylpropyl)-1-oxa-7-azacyclohexadec-6,10-diene-2-carboxamido]-N-methyl-4-methyl-1,3-thiazole-5-carboxamide |
| Other names |
DM4 Maytansinoid DM4 Mertansine |
| Pronunciation | /ˈdiːˈɛmˈfɔːr ˌmeɪtænˈsiːn ˈdiːˈɛmˈfɔːr/ |
| Identifiers | |
| CAS Number | 116855-83-9 |
| 3D model (JSmol) | ``` 3dmol-bio://3D-COQ ``` |
| Beilstein Reference | 3923896 |
| ChEBI | CHEBI:52715 |
| ChEMBL | CHEMBL2110975 |
| ChemSpider | 24277931 |
| DrugBank | DB15866 |
| ECHA InfoCard | The ECHA InfoCard of product 'Dm4 / Maytansine Dm4' is: **"03d94c7b-0b4e-4c95-98a9-6c751e918216"** |
| EC Number | 242-505-3 |
| Gmelin Reference | 1315076 |
| KEGG | C14170 |
| MeSH | Maytansine |
| PubChem CID | 121304016 |
| RTECS number | SWG6806R0K |
| UNII | I3Y58NZG6B |
| UN number | UN3462 |
| CompTox Dashboard (EPA) | DTXSID40941638 |
| Properties | |
| Chemical formula | C44H62ClN4O10S |
| Molar mass | 738.98 g/mol |
| Appearance | White to off-white solid |
| Density | 0.96 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 2.98 |
| Acidity (pKa) | acidic pKa = 7.62 |
| Basicity (pKb) | 6.86 |
| Refractive index (nD) | 1.561 |
| Dipole moment | 3.5 ± 0.5 D |
| Pharmacology | |
| ATC code | V10AX05 |
| Hazards | |
| Main hazards | May damage fertility or the unborn child. Fatal if swallowed, in contact with skin or if inhaled. Causes damage to organs. |
| GHS labelling | GHS05, GHS06, GHS08 |
| Pictograms | GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H302 + H332: Harmful if swallowed or if inhaled. |
| Precautionary statements | P261, P264, P270, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362+P364, P405, P501 |
| Lethal dose or concentration | LD50 (rat, intravenous): 232 µg/kg |
| LD50 (median dose) | 1.5 mg/kg |
| PEL (Permissible) | 0.005 mg/m3 |
| REL (Recommended) | 0.87 mg/m² |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Maytansine DM1 Ansamitocin P-3 |
